Literature DB >> 16417257

Poly(glycoamidoamine)s for gene delivery: stability of polyplexes and efficacy with cardiomyoblast cells.

Yemin Liu1, Theresa M Reineke.   

Abstract

Polymeric vectors have potential as nucleic acid delivery vehicles for novel gene therapy and oligonucleotide treatments for cardiovascular disease. In this report, poly(glycoamidoamine)s that contain four secondary amines and either two or four hydroxyl units in the repeat unit with D-glucarate (D4), meso-galactarate (G4), D-mannarate (M4), and l-tartarate (T4) stereochemistry have been investigated for their pDNA-binding affinity, DNase protection effect, and polyplex stability in the presence of salt and serum. Also, the luciferase gene delivery and cellular internalization of polyplexes formed with these polymers have been investigated with rat cardiomyoblast [H9c2(2-1)] cells. The results demonstrate that the number of hydroxyl groups and the stereochemistry affect the biological properties. Polymers T4 and G4 have higher pDNA binding affinity, protect pDNA from nuclease degradation, and do not release pDNA in the presence of serum. Polymers D4 and M4 bind pDNA with lower affinity, which allows for some pDNA degradation and release in the presence of serum. Although T4 forms the most stable polyplexes, vector G4 reveals the highest luciferase gene expression in serum-free media and the greatest cellular internalization of fluorescein-labeled pDNA both in serum-free and serum-supplemented media. The results of these studies indicate that the polymer-DNA binding affinity, nuclease protection capability, and polyplex stability are important parameters to facilitate effective pDNA delivery with poly(glycoamidoamine)s in cultured cardiomyoblast cells. The carbohydrate type also plays an important role to increase cellular uptake and gene expression where the polymer with the galactarate stereochemistry (in G4) is found to be the most effective vector for pDNA delivery to cardiomyoblast cells in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417257     DOI: 10.1021/bc050275+

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  20 in total

1.  Highlighting the role of polymer length, carbohydrate size, and nucleic acid type in potency of glycopolycation agents for pDNA and siRNA delivery.

Authors:  Lian Xue; Nilesh P Ingle; Theresa M Reineke
Journal:  Biomacromolecules       Date:  2013-10-16       Impact factor: 6.988

2.  Reducible poly(amido ethylenediamine) for hypoxia-inducible VEGF delivery.

Authors:  Lane V Christensen; Chien-Wen Chang; James W Yockman; Rafe Conners; Heidi Jackson; Zhiyuan Zhong; Jan Feijen; David A Bull; Sung Wan Kim
Journal:  J Control Release       Date:  2006-12-28       Impact factor: 9.776

3.  Polymeric nucleic acid vehicles exploit active interorganelle trafficking mechanisms.

Authors:  Katye M Fichter; Nilesh P Ingle; Patrick M McLendon; Theresa M Reineke
Journal:  ACS Nano       Date:  2012-12-31       Impact factor: 15.881

4.  Polymer-peptide delivery platforms: effect of oligopeptide orientation on polymer-based DNA delivery.

Authors:  Sangram S Parelkar; Rachel Letteri; Delphine Chan-Seng; Olga Zolochevska; Jayne Ellis; Marxa Figueiredo; Todd Emrick
Journal:  Biomacromolecules       Date:  2014-03-07       Impact factor: 6.988

5.  Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers.

Authors:  Chad T Greco; Thomas H Epps; Millicent O Sullivan
Journal:  J Vis Exp       Date:  2017-07-21       Impact factor: 1.355

6.  In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo.

Authors:  Michael Tranter; Yemin Liu; Suiwen He; James Gulick; Xiaoping Ren; Jeffrey Robbins; W Keith Jones; Theresa M Reineke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

7.  ENDOCYTOSIS PATHWAYS FOR NUCLEIC ACID THERAPEUTICS.

Authors:  Amanda P Malefyt; S Patrick Walton; Christina Chan
Journal:  Nano Life       Date:  2012-09-01

Review 8.  Novel polymer carriers and gene constructs for treatment of myocardial ischemia and infarction.

Authors:  James W Yockman; Andrew Kastenmeier; Harold M Erickson; Jonathan G Brumbach; Matthew G Whitten; Aida Albanil; Dean Y Li; Sung Wan Kim; David A Bull
Journal:  J Control Release       Date:  2008-07-06       Impact factor: 9.776

Review 9.  Women and heart disease--physiologic regulation of gene delivery and expression: bioreducible polymers and ischemia-inducible gene therapies for the treatment of ischemic heart disease.

Authors:  James W Yockman; Sung Wan Kim; David A Bull
Journal:  Adv Drug Deliv Rev       Date:  2009-05-05       Impact factor: 15.470

10.  Peptide-functionalized poly(ethylene glycol) star polymers: DNA delivery vehicles with multivalent molecular architecture.

Authors:  Katye M Fichter; Le Zhang; Kristi L Kiick; Theresa M Reineke
Journal:  Bioconjug Chem       Date:  2007-10-04       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.